---
title: "武汉友芝友生物制药股份有限公司 (02496.HK)"
type: "quote"
locale: "en"
url: "https://longbridge.com/en/quote/02496.HK.md"
symbol: "02496.HK"
name: "武汉友芝友生物制药股份有限公司"
industry: "生物技术"
---

# 武汉友芝友生物制药股份有限公司 (02496.HK)

| Item | Detail |
|------|--------|
| Industry | 生物技术 |
| Location | 港股市场 |
| Website | [www.yzybio.com](https://www.yzybio.com) |

## Company Profile

Wuhan YZY Biopharma Co Ltd is a China-based company principally engaged in the research, development, production and sales of pharmaceuticals. The Company is mainly engaged in the research, development and industrialization of bispecific antibody drugs. The Company's main products include anti-PD1&a...

## Financial Score

> *Longbridge Financial Score™ — Proprietary multi-factor rating model by [Longbridge](https://longbridge.com). This score is independently calculated by Longbridge and is not affiliated with any third-party rating agency.*
> Updated: 2026-02-28T04:30:14.000Z

**Overall: C (0.55)**

**Industry**: Biotechnology

| Metric | Value |
|--------|-------|
| Industry Ranking | 36 / 53 |
| Industry Median | C |
| Industry Average | C |

- **Style**: Blend - Stocks in which the company has both growth and mature businesses.
- **Scale**: Small - The company's operation has a high degree of growth and volatility, making it easy to achieve high investment returns.

### Score Analysis

**Style Score**: 

#### Growth Score: 

| Indicator | Value | Rating |
|-----------|-------|--------|
| Revenue YoY | 3934.19% |  |
| Net Profit YoY | 57.42% |  |

#### Value Score: 

| Indicator | Value | Rating |
|-----------|-------|--------|
| P/B Ratio | -46.63 |  |
| Dividend Ratio | 0.00% |  |


**Size Score**: 

#### Market Cap Score: 

| Indicator | Value | Rating |
|-----------|-------|--------|
| Market Cap | 1.40B |  |

#### Revenue Score: 

| Indicator | Value | Rating |
|-----------|-------|--------|
| Revenue | 161.96M |  |


**Multi Score**: C

#### Profit Score: E

| Indicator | Value | Rating |
|-----------|-------|--------|
| ROE | -704.81% | E |
| Profit Margin | -52.25% | E |
| Gross Margin | 33.47% | C |

#### Growth Score: B

| Indicator | Value | Rating |
|-----------|-------|--------|
| Revenue YoY | 3934.19% | A |
| Net Profit YoY | 57.42% | B |
| Total Assets YoY | -6.11% | D |
| Net Assets YoY | -156.37% | E |

#### Cash Score: B

| Indicator | Value | Rating |
|-----------|-------|--------|
| Cash Flow Margin | -191.38% | D |
| OCF YoY | 3934.19% | A |

#### Operating Score: B

| Indicator | Value | Rating |
|-----------|-------|--------|
| Turnover | 0.60 | B |

#### Debt Score: E

| Indicator | Value | Rating |
|-----------|-------|--------|
| Gearing Ratio | 111.45% | E |


```chart-data:radar
{
  "title": "Longbridge Financial Score - 武汉友芝友生物制药股份有限公司",
  "chart_type": "radar",
  "dimensions": [
    {
      "name": "Profit",
      "grade": "E",
      "indicators": [
        {
          "name": "ROE",
          "value": "-704.81%",
          "rating": "E"
        },
        {
          "name": "Profit Margin",
          "value": "-52.25%",
          "rating": "E"
        },
        {
          "name": "Gross Margin",
          "value": "33.47%",
          "rating": "C"
        }
      ]
    },
    {
      "name": "Growth",
      "grade": "B",
      "indicators": [
        {
          "name": "Revenue YoY",
          "value": "3934.19%",
          "rating": "A"
        },
        {
          "name": "Net Profit YoY",
          "value": "57.42%",
          "rating": "B"
        },
        {
          "name": "Total Assets YoY",
          "value": "-6.11%",
          "rating": "D"
        },
        {
          "name": "Net Assets YoY",
          "value": "-156.37%",
          "rating": "E"
        }
      ]
    },
    {
      "name": "Cash",
      "grade": "B",
      "indicators": [
        {
          "name": "Cash Flow Margin",
          "value": "-191.38%",
          "rating": "D"
        },
        {
          "name": "OCF YoY",
          "value": "3934.19%",
          "rating": "A"
        }
      ]
    },
    {
      "name": "Operating",
      "grade": "B",
      "indicators": [
        {
          "name": "Turnover",
          "value": "0.60",
          "rating": "B"
        }
      ]
    },
    {
      "name": "Security",
      "grade": "E",
      "indicators": [
        {
          "name": "Gearing Ratio",
          "value": "111.45%",
          "rating": "E"
        }
      ]
    }
  ]
}
```

### Peer Comparison

| Rank | Name | Profit | Growth | Operation | Security | Cash | Rating |
|------|------|--------|--------|-----------|----------|------|--------|
| 01 | 百济神州 (HK.6160) | B | A | B | C | A | B |
| 02 | 信达生物 (HK.1801) | B | A | C | B | A | B |
| 03 | 三生制药 (HK.1530) | A | B | C | A | C | B |
| 04 | 百奥赛图-B (HK.2315) | A | A | C | D | B | B |
| 05 | 和铂医药-B (HK.2142) | A | A | C | B | B | B |

## Valuation Analysis

| Metric | Current | Industry Ranking | High | Median | Low |
|--------|---------|-----------------|------|--------|-----|
| PE (TTM) | -16.40 | 44/70 | - | - | - |
| PB | -46.63 | 69/70 | 32.92 | 28.81 | 24.75 |
| PS (TTM) | 8.83 | 21/70 | 9.45 | 8.64 | 7.68 |
| Dividend Yield | 0.00% | - | - | - | - |

## References

- [Company Overview](https://longbridge.com/en/quote/02496.HK/overview.md) - Shareholders, executives, business segments
- [Financials](https://longbridge.com/en/quote/02496.HK/norm.md) - Income statement, balance sheet, cash flow, distribution plan
- [Topics & Discussions](https://longbridge.com/en/quote/02496.HK/topics.md) - Community topics and discussions

---

> **Disclaimer**: This article is for reference only and does not constitute any investment advice.